General Information of Drug (ID: DMTOEJX)

Drug Name
Acid-activated omeprazole Drug Info
Synonyms
Hydroxyfasudil; HYDROXYFASUDIL; 105628-72-6; Hydroxy-Fasudil; 1-(1-Hydroxy-5-isoquinolinesulfonyl)homopiperazine; HA 1100; HA-1100; 1-[(1,2-DIHYDRO-1-OXO-5-ISOQUINOLINYL)SULFONYL]HEXAHYDRO-1H-1,4-DIAZEPINE; CHEMBL1233300; Hexahydro-1-((1,2-dihydro-1-oxo-5-isoquinolinyl)sulfonyl)-1H-1,4-diazepine; 5-(1,4-diazepane-1-sulfonyl)-1,2-dihydroisoquinolin-1-one; HYDROXYFASUDIL;5-(1,4-diazepan-1-ylsulfonyl)-2H-isoquinolin-1-one; 1H-1,4-Diazepine, hexahydro-1-((1,2-dihydro-1-oxo-5-isoquinolinyl)sulfonyl)-; HFS; 2etk; 2erz; AC1MI8J4; SCHEMBL123699
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
3064778
CAS Number
CAS 105628-72-6
TTD Drug ID
DMTOEJX
VARIDT Drug ID
DR00804

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Chloride channel protein 2 (CLC-2) TT30NW6 CLCN2_HUMAN Activator [1]
Rho-associated protein kinase 1 (ROCK1) TTZN7RP ROCK1_HUMAN Inhibitor [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Chloride channel protein 2 (CLC-2) DTT CLCN2 2.868 6.238 5.57 4.129
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Discovery agent
ICD Disease Classification N.A.
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Chloride channel protein 2 (CLC-2) DTT CLCN2 8.78E-02 -0.01 -0.06
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClC-2 Cl- channels in human lung epithelia: activation by arachidonic acid, amidation, and acid-activated omeprazole. Am J Physiol Cell Physiol. 2001 Jul;281(1):C46-54.
2 Long-term treatment with a specific Rho-kinase inhibitor suppresses cardiac allograft vasculopathy in mice. Circ Res. 2004 Jan 9;94(1):46-52.